King of Prussia,
Anidulafungin is a medicine being developed for treatment of adults with certain kinds of
fungal infections. This study is evaluating anidulafungin in children and adolescents who
have fever and a low white blood cell count (neutropenia).
Anidulafungin is an investigational drug being developed as an intravenous treatment for
esophageal candidiasis, candidemia and other invasive fungal infections. Anidulafungin is
an antifungal agent of the echinocandin class, which targets the fungal cell wall of yeast
and other filamentous fungi.
- Children ages 2-17 years with fever and neutropenia.
- The expected duration of neutropenia should be 10 days and due to cytotoxic
chemotherapy or aplastic anemia.